Vitrification with shortened equilibration across human embryonic developmental stages: a proof-of-concept study.

Area of Science:

• Reproductive Medicine
• Embryology
• Cryobiology

Background:

• Vitrification with shortened equilibration has shown promise in mouse models and human oocytes.
• Clinical evidence for shortened equilibration vitrification in human embryos is limited, with no current regulatory approval.
• This study investigates the safety and efficacy of shortened equilibration vitrification in human embryos.

Purpose of the Study:

• To evaluate if vitrification with a shortened equilibration solution can be safely applied to human embryos.
• To determine if this method compromises key embryological clinical outcomes.
• To assess the feasibility of optimizing vitrification protocols.

Main Methods:

• A prospective proof-of-concept study involving human blastocysts, cleavage-stage embryos, and tripronuclear (3PN) zygotes.
• Comparison of standard vitrification versus shortened-equilibration vitrification using full-volume or microdrop loading.
• Outcomes assessed included post-warming survival, developmental progression, blastocyst formation, and re-expansion rates.

Main Results:

• Shortened equilibration vitrification showed comparable post-warming survival rates (89.2%–100%) across different embryo stages.
• Developmental progression, including day-3 development and blastocyst formation, was similar between standard and shortened equilibration groups.
• Blastocyst re-expansion rates were also comparable, with no significant differences observed after one or two warming cycles.

Conclusions:

• Shortened-equilibration vitrification is associated with comparable survival, developmental progression, and re-expansion rates to standard vitrification.
• The findings support the feasibility of shortening equilibration time without compromising key embryological outcomes.
• Larger studies are needed to validate these findings and potentially optimize clinical vitrification protocols.